QuidelOrtho (QDEL) Projected to Announce Earnings on Tuesday

QuidelOrtho (NASDAQ:QDEL) will likely be announcing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of $0.2023 per share and revenue of $627.83 million for the quarter. QuidelOrtho has set its FY 2026 guidance at 0.650-0.900 EPS. Parties can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.

QuidelOrtho (NASDAQ:QDEL) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.18. QuidelOrtho had a negative net margin of 39.20% and a positive return on equity of 4.88%. The firm had revenue of $630.90 million during the quarter, compared to analysts’ expectations of $618.72 million. During the same period in the previous year, the company earned $0.12 earnings per share. The firm’s quarterly revenue was up 2.8% on a year-over-year basis. On average, analysts expect QuidelOrtho to post $0.75 EPS for the current fiscal year and $1.45 EPS for the next fiscal year.

QuidelOrtho Stock Performance

Shares of QDEL stock opened at $13.25 on Monday. The company has a current ratio of 1.39, a quick ratio of 0.76 and a debt-to-equity ratio of 1.43. QuidelOrtho has a 12-month low of $9.92 and a 12-month high of $35.58. The stock has a market capitalization of $908.55 million, a P/E ratio of -0.86 and a beta of 0.77. The firm’s 50 day moving average is $12.76 and its 200 day moving average is $16.47.

Analyst Ratings Changes

Several brokerages have weighed in on QDEL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Thursday, October 15th. Zacks Research raised shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a research note on Friday, October 9th. Finally, Citigroup raised their price objective on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Four research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, QuidelOrtho presently has an average rating of “Reduce” and a consensus price target of $13.62.

QuidelOrtho Company Profile

QuidelOrtho Corporation (NASDAQ:QDEL) is a global in vitro diagnostics company formed through the combination of Quidel Corporation and Ortho Clinical Diagnostics, a transaction completed in 2022. The company develops, manufactures and markets diagnostic technologies used to detect disease, guide treatment decisions and support blood-transfusion safety.

Its portfolio includes rapid immunoassays, molecular testing systems, clinical chemistry and immunohematology products, as well as laboratory automation solutions.